🇺🇸 FDA
Pipeline program

Dasatinib

XJTU1AF-CRF-2020-002-1

Unknown small_molecule active

Quick answer

Dasatinib for Precursor Cell Lymphoblastic Leukemia-Lymphoma is a Unknown program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phase
Unknown
Modality
small_molecule
Status
active

Clinical trials